FDA and EMA chief medical officers don’t expect ChatGPT to help with drug reviews anytime soon

BOSTON — The myr­i­ad us­es of Chat­G­PT and oth­er large lan­guage mod­els have spread like wild­fire, but the two chief med­ical of­fi­cers at the US Food and Drug Ad­min­is­tra­tion and the Eu­ro­pean Med­i­cines Agency said yes­ter­day that they aren’t about to start us­ing the new tech to speed up drug re­views.

“I have one big con­cern and that’s garbage in, garbage out,” Stef­fen Thirstrup, CMO of EMA, told at­ten­dees at the Drug In­for­ma­tion As­so­ci­a­tion an­nu­al con­fer­ence on Thurs­day. “These mod­els on­ly pick up what’s been pub­lished. That’s the tip of the ice­berg.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN